COMPOUNDS AND METHODS OF PROPHYLAXIS AND TREATMENT REGARDING NICOTINIC RECEPTOR ANTAGONISTS
    7.
    发明申请
    COMPOUNDS AND METHODS OF PROPHYLAXIS AND TREATMENT REGARDING NICOTINIC RECEPTOR ANTAGONISTS 审中-公开
    关于NICOTINIC受体拮抗剂的预防和治疗的化合物和方法

    公开(公告)号:US20160008343A1

    公开(公告)日:2016-01-14

    申请号:US14742570

    申请日:2015-06-17

    IPC分类号: A61K31/454 A61K45/06

    摘要: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.

    摘要翻译: 本发明的目的是本文公开的新型烟碱受体拮抗剂可用于广泛的临床或药用方面。 例如,本发明的预期用途是使用新颖的烟碱受体拮抗剂来抑制非小细胞肺癌细胞的生长周期。 不受理论的约束,本发明的目的是认为本文公开的烟碱型受体拮抗剂具有可逆结合性质。 此外,本发明的化合物对于0.7nAChR是选择性的。 例如,本发明的化合物不被认为与0.4(32 nAChR)神经肌肉受体结合,也可以考虑将本发明的烟碱受体拮抗剂用作治疗暴露或潜在暴露的对策, 到各种潜在的神经毒素。